Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer

Cancer

Volumn 117, Issue 13, 2011, Pages 2883-2891

  Boorjian, Stephen A ^a   Karnes, R Jeffrey ^a   Viterbo, Rosalia ^b   Rangel, Laureano J ^a   Bergstralh, Eric J ^a   Horwitz, Eric M ^b   Blute, Michael L ^a   Buyyounouski, Mark K ^b  

^a MAYO CLINIC COLLEGE OF MEDICINE   (United States)

^b FOX CHASE CANCER CENTER   (United States)

Author keywords

androgen deprivation therapy; prostate cancer; prostate specific antigen; radiation therapy; radical prostatectomy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER GROWTH; CANCER MORTALITY; CANCER SURVIVAL; CONTROLLED STUDY; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GLEASON SCORE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; SURVIVAL RATE; SURVIVAL TIME; TUMOR CLASSIFICATION;

AGED; ANDROGEN ANTAGONISTS; ANDROGENS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROPORTIONAL HAZARDS MODELS; PROSTATE; PROSTATECTOMY; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 79959624878     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25900     Document Type: Article

References (45)

1. Scardino P., Update: NCCN prostate cancer Clinical Practice Guidelines. J Natl Compr Canc Netw. 2005; 3 (suppl 1): S29-S33.
2. Cooperberg MR, Lubeck DP, Mehta SS, Carroll PR., Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE). J Urol. 2003; 170: S21-S25.
3. Lawton CA, Winter K, Murray K, et al. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) Trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2001; 49: 937-946. (Pubitemid 32184600)
4. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomized trial. Lancet. 2002; 360: 103-108. (Pubitemid 34786197)
5. Hanks GE, Pajak TF, Porter A, et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol. 2003; 21: 3972-3978. (Pubitemid 46606211)
6. Roach M 3rd, Bae K, Speight J, et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol. 2008; 26: 585-591. (Pubitemid 351264352)
7. Widmark A, Klepp O, Solberg A, et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomized phase III trial. Lancet. 2009; 373: 301-308.
8. Bolla M, de Reijke TM, Van Tienhoven G, et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med. 2009; 360: 2516-2527.
9. Boorjian SA, Karnes RJ, Rangel LJ, Bergstralh EJ, Blute ML., Mayo Clinic validation of the D'Amico risk group classification for predicting survival following radical prostatectomy. J Urol. 2008; 179: 1354-1361.
10. Yossepowitch O, Eggener SE, Serio AM, et al. Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy. Eur Urol. 2008; 53: 950-959. (Pubitemid 351434496)
11. Meng MV, Elkin EP, Latini DM, Duchane J, Carroll PR., Treatment of patients with high risk localized prostate cancer: results from Cancer of the Prostate Strategic Urological Research Endeavor (CaPSURE). J Urol. 2005; 173: 1557-1561. (Pubitemid 40528444)
12. Tewari A, Divine G, Chang P, et al. Long-term survival in men with high grade prostate cancer: a comparison between conservative treatment, radiation therapy and radical prostatectomy-a propensity scoring approach. J Urol. 2007; 177: 911-915. (Pubitemid 46216365)
13. Nguyen PL, Chen MH, Catalona WJ, Moul JW, Sun L, D'Amico AV., Predicting prostate cancer mortality among men with intermediate to high-risk disease and multiple unfavorable risk factors. Int J Radiat Oncol Biol Phys. 2009; 73: 659-664.
14. Klein EA, Ciezki J, Kupelian PA, Mahadevan A., Outcomes for intermediate risk prostate cancer: are there advantages for surgery, external radiation, or brachytherapy? Urol Oncol. 2009; 27: 67-71.
15. Zelefsky MJ, Eastham JA, Cronin AM, et al. Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix. J Clin Oncol. 2010; 28: 1508-1513.
16. Cooperberg MR, Vickers AJ, Broering JM, Carroll PR., Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. Cancer. 2010; 116: 5226-5234.
17. Jeldres C, Suardi N, Perrotte P, et al. Survival after radical prostatectomy and radiotherapy for prostate cancer: a population-based study. Can Urol Assoc J. 2009; 3: 13-21.
18. Fletcher SG, Mills SE, Smolkin ME, Theodorescu D., Case-matched comparison of contemporary radiation therapy to surgery in patients with locally advanced prostate cancer. Int J Radiat Oncol Biol Phys. 2006; 66: 1092-1099. (Pubitemid 44633512)
19. Arcangeli G, Strigari L, Arcangeli S, et al. Retrospective comparison of external beam radiotherapy and radical prostatectomy in high-risk, clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2009; 75: 975-982.
20. D'Amico AV, Whittington R, Kaplan I, et al. Equivalent biochemical failure-free survival after external beam radiation therapy or radical prostatectomy in patients with a pretreatment prostate specific antigen of >4-20 ng/mL. Int J Radiat Oncol Biol Phys. 1997; 15: 1053-1058. (Pubitemid 27230029)
21. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998; 280: 969-974. (Pubitemid 28445094)
22. Kupelian PA, Elshaikh M, Reddy CA, Zippe C, Klein EA., Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy. J Clin Oncol. 2002; 20: 3376-3385.
23. Akakura K, Suzuki H, Ichikawa T, et al. A randomized trial comparing radical prostatectomy plus endocrine therapy versus external beam radiotherapy plus endocrine therapy for locally advanced prostate cancer: results at median follow-up of 102 months. Jpn J Clin Oncol. 2006; 36: 789-793. (Pubitemid 47090734)
24. Cooperberg MR, Broering JM, Carroll PR., Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol. 2010; 28: 1117-1123.
25. Greene FL,. Prostate., Fleming JD, Page FL, Fleming ID, et al, eds. AJCC Staging Manual. 6th ed. New York: Springer-Verlag; 2002: 309-316.
26. Charlson ME, Pompei P, Ales KL, MacKenzie CR., A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis. 1987; 40: 373-383. (Pubitemid 17055592)
27. Pollack A, Hanlon AL, Horwitz EM, et al. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. Int J Radiat Oncol Biol Phys. 2006; 64: 518-526. (Pubitemid 43083441)
28. Morgan PB, Hanlon AL, Horwitz EM, Buyyounouski MK, Uzzo RG, Pollack A., Timing of biochemical failure and distant metastatic disease for low-, intermediate-, and high-risk prostate cancer after radiotherapy. Cancer. 2007; 110: 68-80. (Pubitemid 46986420)
29. Fine JP, Gray RJ., A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999; 94: 496-509.
30. Kuban DA, Levy LB, Cheung MR, et al. Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease [published online ahead of print May 20, 2010]? Int J Radiat Oncol Biol Phys. 2010.
31. Horwitz EM, Bae K, Hanks GE, et al. Ten-year follow-up of Radiation Therapy Oncology Group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol. 2008; 26: 2497-2504.
32. Stephenson AJ, Kattan MW, Eastham JA, et al. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol. 2009; 27: 4300-4305.
33. Kane CJ, Presti JC, Amling CL, Aronson WJ, Terris MK, Freedland SJ., Changing nature of high risk patients undergoing radical prostatectomy. J Urol. 2007; 177: 113-117. (Pubitemid 44895334)
34. Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008; 358: 1250-1261. (Pubitemid 351439226)
35. Smith MR, O'Malley AJ, Keating NL., Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006; 24: 448-4456.
36. Barry MJ, Albertsen PC, Bagshaw MA, et al. Outcomes for men with clinically nonmetastatic prostate carcinoma managed with radical prostatectomy, external beam radiotherapy, or expectant management. Cancer. 2001; 91: 2302-2314. (Pubitemid 32552816)
37. Nanda A, Chen MH, Braccioforte MH, Moran BJ, D'Amico AV., Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. JAMA. 2009; 302: 866-873.
38. Levine GN, D'Amico AV, Berger P, et al. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. CA Cancer J Clin. 2010; 60: 194-201.
39. Paulson DF, Lin GH, Hinshaw W, Stephani S., Radical surgery versus radiotherapy for adenocarcinoma of the prostate. J Urol. 1982; 128: 502-504. (Pubitemid 12037692)
40. Cox J, Grignon D, Kaplan R, et al. Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys. 1997; 37: 1035-1041. (Pubitemid 27230027)
41. Roach M 3rd, Hanks G, Thames H Jr, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006; 65: 965-974.
42. Nielsen ME, Makarov DV, Humphreys E, Mangold L, Partin AW, Walsh PC., Is it possible to compare PSA recurrence-free survival after surgery and radiotherapy using revised ASTRO criterion-"nadir+2? Urology. 2008; 72: 389-395.
43. Ward JF, Blute ML, Slezak J, Bergstralh EJ, Zincke H., The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy. J Urol. 2003; 170: 1872-1876. (Pubitemid 37254948)
44. Roehl KA, Han M, Ramos CG, Antenor JA, Catalona WJ., Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3478 consecutive patients: long-term results. J Urol. 2004; 172: 910-914. (Pubitemid 39096421)
45. Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005; 294: 433-439. (Pubitemid 41124175)